


Reduction of Eyedrop Volume for Topical Ophthalmic Medications with the Nanodropper Bottle Adaptor

St. Peter DM, Steger JS, Patnaik JL, Davis N, Kahook MY, Seibold LK
doi: 10.2147/MDER.S397654. Published Apr 2023.



Nanodropper extends bottle-life by 2.6x


Published in Ophthalmology



Randomized Trial to Evaluate the Efficacy of the Nanodropper Device for Pupillary Dilation and Cycloplegia in Children

Hoppe CB, Yonamine S, Kao BW, Turner ML, Ou Y, Han Y, Keenan JD, Oatts JT
doi: 10.1016/j.ophtha.2022.10.016. Published Mar 2023.

Clinicaltrials.gov: NCT05274321



Non-inferiority of mydriatic microdrops established for maximum pupil diameter



Published in Ophthalmology



An Evaluation of the Efficacy and Safety of Timolol Maleate 0.5% Microdrops Administered with the Nanodropper®

Steger JS, Durai I, Odayappan A, Raman R, Sruthi T, Song AJ, Puthuran G, Venkatesh R, Colantuoni E, Robin AL
doi: https://doi.org/10.1016/j.ophtha.2024.03.012. Published Mar 2024.

Clinicaltrials.gov: NCT05181046



No between-group difference in IOP at any time point
Microdrops reduced HR significantly less than conventional drops

Twelve-Week Randomized, Controlled, Non-Inferiority Trial Evaluating the Safety and Efficacy of IOP-Lowering Microdrops Administered with the Nanodropper® Adaptor in Glaucoma Patients

Steger JS, Capó-Aponte JE, Papp A, Schulte AJ, Song AJ, Colantuoni E, Kelstrom JC

Manuscript in preparation


Presented at



Clinicaltrials.gov: NCT05844384

Mean intraocular pressure (IOP) at baseline and 12 weeks ^a				
	Conventional drops (n = 30)	Microdrops (n = 29)	Microdrops – Conventional drops (n = 29)	
IOP, mm Hg				
Baseline	16.37 ± 2.85		Mean difference (95% CI)	Met non-inferiority criteria
12 weeks	16.23 ± 2.78	14.93 ± 2.94	-1.41 (-2.09 to -0.73)*	Yes
Change from baseline	-0.13 (-0.52 to 0.26)	-1.59 (-2.29 to -0.88)*	-1.41 (-2.09 to -0.73)*	
% Change from baseline	-0.56 (-2.89 to 1.77)	-9.35 (-13.44 to -5.26)*	-8.48 (-12.48 to -4.49)*	


^aValues are expressed as mean ± SD or mean (95% CI)
*p<0.05




Non-inferiority and superiority of microdrops established

In stable glaucoma patients, microdrops decreased IOP from baseline by 1.6 mm Hg

Early bottle exhaustion (EBE)



Adverse events (AEs)



At 12 weeks

- Microdrops decreased EBE prevalence by 80%^b
- Microdrops decreased AE prevalence by 67%^b

^bRelative to conventional drops at 12 weeks.

*p<0.05

Learn more at nanodropper.com

Legal disclaimer: This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. All statements other than statements of historical facts contained in this presentation, including any statements regarding the timing, objectives, and results of the clinical trials including the complete clinical results of the trial are forward-looking statements. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.